Japan Approves GSK's Antibody Treatment For COVID-19 Patients

28.09.2021 08:27

Sotrovimab will be used for COVID 19 patients with mild symptoms, says Japanese Health Ministry.

Japan on Monday approved GlaxoSmithKline and and Vir Biotechnology's Sotrovimab for treatment of patients with mild COVID-19 symptoms.

Japan's Health Ministry authorized the use of the antibody treatment on the recommendation of a panel of experts.

Sotrovimab, which is administered intravenously, will be used for COVID-19 patients who do not require oxygen supplementation.

Clinical tests showed the drug reduces the risk of hospitalization and death by 79%.​​​​​​​ -

In order to provide you with a better service, we position cookies on our site. Your personal data is collected and processed within the scope of KVKK and GDPR. For detailed information, you can review our Data Policy / Disclosure Text. By using our site, you agree to our use of cookies.', '